Answers are grounded in this paper and cite their sources.
A 51-year-old man with recent orthotopic heart transplant five months earlier, presented to clinic with pre-syncope and 1 week history of diarrhoea including an episode of fecal incontinence. On examination the patient was hypotensive, blood pressure 80/50 mmHg; tachycardic, heart rate 141 beats per minute; and febrile, temperature 38·5oC. There was no obvious focal source of infection on examination. Laboratory investigations showed a new neutropenia, white blood count 1·2 10^9/L (reference range 4.0-11.0), neutrophils 1.0 10^9/L (reference range 2.0-7.5) and c-reactive protein 397 mg/L (reference range <5.0). Blood, urine and fecal culture were negative. Ceftriaxone, azithromycin and gentamicin were commenced empirically. Computer tomography scan the following day revealed gas locules within the subcutaneous soft tissue around the anal area (Panel A) and Fournier's gangrene was suspected which required urgent surgical debridement (Panel B). Vancomycin, clindamycin and cefepime were commenced. Tissue culture grew Enterococcus faecalis and Escherichia coli. In total seven debridement procedures were needed and fecal diversion with colostomy was required. Post-transplant diabetes mellitus had been diagnosed 3 months earlier with HbA1c 7.0 % (53 mmol/mol) and fasting glucose 18.7 mmol/L. Insulin isophane, insulin aspart and empagliflozin 10 mg had been commenced at diagnosis of diabetes, followed by metformin 500 mg daily. Insulin was weaned prior to presentation with Fournier’s gangrene based on glucose levels <10 mmol/L. Immunosuppression included everolimus (commenced 1 month prior to presentation with Fournier’s gangrene), tacrolimus, mycophenolate and prednisolone (8 mg at time of presentation). This is the first reported case of Fournier’s gangrene with sodium glucose co-transporter 2 (SGLT2) inhibitor use in a solid organ transplant recipient. Fournier’s gangrene is a rare but reported adverse event associated with SGLT2 inhibitor use.1Bersoff-Matcha S.J. Chamberlain C. Cao C. Kortepeter C. Chong W.H. Fournier Gangrene Associated With Sodium–Glucose Cotransporter-2 Inhibitors.Ann Intern Med. 2019 Jun 4; 170: 764-769Crossref PubMed Scopus (0) Google Scholar Fournier’s gangrene is characterised by necrotising fasciitis around the genital and/or perianal regions and requires surgical debridement. The incidence of Fournier’s gangrene is estimated to be 1.6/100,000 in males in America, with limited ability to estimate in females.2Sorensen M.D. Krieger J.N. Rivara F.P. Broghammer J.A. Klein M.B. Mack C.D. et al.Fournier’s Gangrene: population based epidemiology and outcomes.J Urol. 2009 May; 181: 2120-2126Crossref PubMed Scopus (189) Google Scholar Diabetes itself is associated with increased risk of Fournier’s gangrene.3Nisbet A.A. Thompson I.M. Impact of diabetes mellitus on the presentation and outcomes of Fournier’s gangrene.Urology. 2002 Nov 1; 60: 775-779Abstract Full Text Full Text PDF PubMed Scopus (0) Google Scholar, 4Tang L.M. Su Y.J. Lai Y.C. The evaluation of microbiology and prognosis of fournier’s gangrene in past five years.SpringerPlus. 2015 Jan 13; 414Crossref Scopus (47) Google Scholar, 5Taylor L. Asmar O. Mandal A. Tridente A. Hardy K. Shokrollahi K. Perspectives From a Regional Plastic Surgery Centre on Evidence for the Purported Link Between SGLT2 Inhibitors and Fournier’s Gangrene.Front Surg. 2021 Dec 10; 8754101Crossref Scopus (1) Google Scholar There are case reports of Fournier’s gangrene associated with alternative diabetes medications, other than SGLT2 inhibitors.1Bersoff-Matcha S.J. Chamberlain C. Cao C. Kortepeter C. Chong W.H. Fournier Gangrene Associated With Sodium–Glucose Cotransporter-2 Inhibitors.Ann Intern Med. 2019 Jun 4; 170: 764-769Crossref PubMed Scopus (0) Google Scholar, 5Taylor L. Asmar O. Mandal A. Tridente A. Hardy K. Shokrollahi K. Perspectives From a Regional Plastic Surgery Centre on Evidence for the Purported Link Between SGLT2 Inhibitors and Fournier’s Gangrene.Front Surg. 2021 Dec 10; 8754101Crossref Scopus (1) Google Scholar Immunosuppression and corticosteroid use, such as that required in organ transplant recipients, are also risk factors for Fournier’s gangrene.3Nisbet A.A. Thompson I.M. Impact of diabetes mellitus on the presentation and outcomes of Fournier’s gangrene.Urology. 2002 Nov 1; 60: 775-779Abstract Full Text Full Text PDF PubMed Scopus (0) Google Scholar, 4Tang L.M. Su Y.J. Lai Y.C. The evaluation of microbiology and prognosis of fournier’s gangrene in past five years.SpringerPlus. 2015 Jan 13; 414Crossref Scopus (47) Google Scholar The most common pathogens are polymicobial organisms, Escherichia coli and Streptococcus.4Tang L.M. Su Y.J. Lai Y.C. The evaluation of microbiology and prognosis of fournier’s gangrene in past five years.SpringerPlus. 2015 Jan 13; 414Crossref Scopus (47) Google Scholar The exact mechanism of the development of Fournier’s gangrene is unknown. It is postulated that small abrasions may facilitate entry of pathogens into the soft tissue and these pathogens release collagenase enzymes causing tissue damage with rapid spread. Diabetes and the use of SGLT2 inhibitors cause glucosuria which creates a favourable environment for bacterial and fungal infections. However, the causal relationship between SGLT2 inhibitors and Fournier’s gangrene is questionable.5Taylor L. Asmar O. Mandal A. Tridente A. Hardy K. Shokrollahi K. Perspectives From a Regional Plastic Surgery Centre on Evidence for the Purported Link Between SGLT2 Inhibitors and Fournier’s Gangrene.Front Surg. 2021 Dec 10; 8754101Crossref Scopus (1) Google Scholar In summary, patients who are immunosuppressed and have diabetes may be at higher risk of developing Fournier’s gangrene with SGLT2 inhibitor use due to concomitant risk factors. With increasing therapeutic indications, pharmacovigilance of this rare event, particularly in those on immunosuppression is required. This report did not receive any funding. The authors have no conflicts of interest to declare. LMR is supported by a Scholarship (107026) from the National Heart Foundation of Australia. LMR & JRG were involved in the writing of the original draft and review; JYC, PSM and AJ were involved in the writing, review and editing. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
No takes yet. Share an insight, caveat, or question.
Raven et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: